<DOC>
	<DOCNO>NCT00278200</DOCNO>
	<brief_summary>RATIONALE : Vaccines make person 's white blood cell may help body build effective immune response . PURPOSE : This phase I trial study side effect vaccine therapy treating patient consider solid organ transplant risk post-transplant lymphoproliferative disorder .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients Who Are Being Considered For Solid Organ Transplant Are Risk For Post-Transplant Lymphoproliferative Disorder</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine efficacy photochemically-treated autologous Epstein-Barr virus ( EBV ) -transformed B-lymphoblastoid cell vaccine generate EBV-specific T-cell antibody response EBV-negative patient boost response EBV-positive patient consider solid organ transplant high risk post-transplant lymphoproliferative disorder . - Determine adverse event associate vaccine patient . - Determine ability vaccine protect EBV primary infection EBV-seronegative patient time course study . OUTLINE : This nonrandomized , pilot study . Patients stratify accord Epstein-Barr virus ( EBV ) status ( seropositive v seronegative ) . Patients receive photochemically-treated autologous EBV-transformed B-lymphoblastoid cell vaccine intradermally week 0 4 . After completion study treatment , patient follow periodically 5 year . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Being consider solid organ transplant At high risk posttransplant lymphoproliferative disorder PATIENT CHARACTERISTICS : Body weight ≥ 25 kg Karnofsky performance status 50100 % OR Lansky performance status 50100 % Not pregnant Negative pregnancy test Fertile patient must use contraception 2 month completion study treatment Hemoglobin ≥ 8 g/dL ( erythropoietin allow ) No history autoimmune disease , include follow : Systemic lupus erythematosus Sarcoidosis Rheumatoid arthritis Glomerulonephritis Vasculitis No primary immunodeficiency No HIV positivity PRIOR CONCURRENT THERAPY : No corticosteroid 1 month 1 month first study vaccination , except follow : Physiologic steroid dosing ( ≤ 20 mg/day prednisone steroid equivalent ) adrenal insufficiency Inhaled steroid</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>post-transplant lymphoproliferative disorder</keyword>
</DOC>